Accessibility Menu
Ocular Therapeutix logo

Ocular Therapeutix

(NASDAQ) OCUL

Current Price$8.28
Market Cap$1.80B
Since IPO (2014)-35%
5 Year-60%
1 Year+7%
1 Month+18%

Ocular Therapeutix Financials at a Glance

Market Cap

$1.80B

Revenue (TTM)

$51.95M

Net Income (TTM)

$265.94M

EPS (TTM)

$-1.44

P/E Ratio

-5.75

Dividend

$0.00

Beta (Volatility)

1.47 (Average)

Price

$8.28

Volume

69,150

Open

$8.47

Previous Close

$8.28

Daily Range

$8.28 - $8.53

52-Week Range

$5.80 - $16.44

OCUL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ocular Therapeutix

Industry

Pharmaceuticals

Employees

325

CEO

Pravin U. Dugel, MD

Headquarters

Bedford, MA 01730, US

OCUL Financials

Key Financial Metrics (TTM)

Gross Margin

87%

Operating Margin

-5%

Net Income Margin

-5%

Return on Equity

-55%

Return on Capital

-36%

Return on Assets

-33%

Earnings Yield

-17.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.80B

Shares Outstanding

217.69M

Volume

69.15K

Short Interest

0.00%

Avg. Volume

6.15M

Financials (TTM)

Gross Profit

$45.25M

Operating Income

$270.02M

EBITDA

$249.78M

Operating Cash Flow

$204.88M

Capital Expenditure

$12.01M

Free Cash Flow

$216.89M

Cash & ST Invst.

$737.06M

Total Debt

$79.78M

Ocular Therapeutix Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$13.25M

-22.4%

Gross Profit

$11.66M

-26.5%

Gross Margin

87.97%

N/A

Market Cap

$1.80B

N/A

Market Cap/Employee

$6.57M

N/A

Employees

274

N/A

Net Income

$64.65M

-33.6%

EBITDA

$60.58M

-36.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$660.09M

+108.7%

Accounts Receivable

$30.65M

-5.4%

Inventory

$3.56M

+17.2%

Long Term Debt

$74.15M

+0.4%

Short Term Debt

$2.82M

+45.7%

Return on Assets

-32.91%

N/A

Return on Invested Capital

-35.66%

N/A

Free Cash Flow

$57.09M

-44.0%

Operating Cash Flow

$54.25M

-37.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MESOMesoblast Limited
$14.78+1.03%
GLPGGalapagos N.V.
$32.53+1.12%
RCUSArcus Biosciences, Inc.
$22.43+0.99%
VRDNViridian Therapeutics, Inc.
$27.84+0.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$178.83-0.01%
NOKNokia
$8.31-0.01%
VGVenture Global
$14.30-0.04%
TSLATesla
$380.25-0.03%

Questions About OCUL

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.